AB-3PRGD2

• Description :

  AB-3PRGD2 is a radiotherapeutic agent targeting integrin αvβ3. AB-3PRGD2 shows improved tumor uptake and prolonged tumor retention, leading to significantly enhanced tumor growth suppression. AB-3PRGD2 can remodel the tumor immune microenvironment by upregulating PD-L1 expression and increasing tumor-infiltrating CD8+ T cells[1].

• UNSPSC :

  12352005

• Target :

  Integrin; PD-1/PD-L1

• Related Pathways :

  Cytoskeleton; Immunology/Inflammation

• Field of Research :

  Cancer

• Smiles :

  OC(CN(CCN(CCN(CC1)CC(O)=O)CC(O)=O)CCN1CC(N[C@H](C(N[C@@H](C(O)=O)CCCCNC(CCCC2=CC=C(C=C2)I)=O)=O)CSC3C(N(C(C3)=O)CCCCCC(NCCOCCOCCOCCOCCC(N[C@H](C(NCCOCCOCCOCCOCCC(NCCCC[C@@H]4NC([C@H](NC([C@@H](NC(CNC([C@@H](NC4=O)CCCNC(N)=N)=O)=O)CC(O)=O)=O)CC5=CC=CC=C5)=O)=O)=O)CCC(NCCOCCOCCOCCOCCC(NCCCC[C@@H]6NC([C@H](NC([C@@H](NC(CNC([C@@H](NC6=O)CCCNC(N)=N)=O)=O)CC(O)=O)=O)CC7=CC=CC=C7)=O)=O)=O)=O)=O)=O)=O)=O

• Molecular Formula :

  C137H215IN30O45S

• Molecular Weight :

  3161.32

• References & Citations :

  [1]Shi J, et al. Nuclear imaging of PD-L1 expression promotes the synergistic antitumor efficacy of targeted radionuclide therapy and immune checkpoint blockade. Eur J Nucl Med Mol Imaging. 2025 Feb;52 (3) :955-969.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2416165-76-7]